Company Filing History:
Years Active: 2021
Title: Innovator Spotlight: Krista Dubin and Her Groundbreaking Patent
Introduction: Krista Dubin is a prominent inventor based in New York, NY. She has made significant contributions to the medical field, particularly in the area of checkpoint blockade therapy. With a keen focus on understanding the complexities of the intestinal microbiome, Dubin is dedicated to advancing treatment options for patients at risk of developing complications associated with modern cancer therapies.
Latest Patents: Dubin holds a patent titled "Methods and compositions for identifying and treating subjects at risk for checkpoint blockade therapy associated colitis." This innovative patent addresses critical methods and compositions that assist healthcare providers in identifying patients who may be at a higher or lower risk of developing colitis due to checkpoint blockade treatments. The invention is founded on the discovery of specific intestinal microbiota related to the likelihood of developing this condition, including various families within the phyla Bacteroidetes.
Career Highlights: Dubin is currently affiliated with the Memorial Sloan Kettering Cancer Center, a leader in cancer treatment and research. Her work is integral in bridging the gap between basic research and clinical applications, showcasing her dedication to enhancing patient outcomes through scientific inquiry and medical advancement.
Collaborations: Krista Dubin has collaborated with esteemed colleagues, notably Eric G. Pamer and Jedd David Wolchok. These partnerships foster an environment of shared knowledge and expertise, enabling the team to explore uncharted territories in cancer therapy and its implications on patient health.
Conclusion: Krista Dubin stands out as a pioneering inventor whose work holds the potential to transform patient care in the realm of immunotherapy. Through her innovative patent and collaborations, she is paving the way for more effective and personalized treatment strategies for patients facing the challenges of checkpoint blockade therapy. Her dedication to research reflects the spirit of innovation that drives the ongoing progress in medical science.